Mayme Roettig
Geen lopende functies
Profiel
Mayme Lou Roettig worked as a National Director at American Heart Association, Inc. and as an Executive Medical Director at PLx Pharma, Inc. She holds a graduate degree from Loyola University of Chicago and an undergraduate degree from the University of Charleston.
Eerdere bekende functies van Mayme Roettig
| Bedrijven | Functie | Einde |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Chief Tech/Sci/R&D Officer | 01-02-2023 |
American Heart Association, Inc.
 American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Opleiding van Mayme Roettig
| Loyola University of Chicago | Graduate Degree |
| University of Charleston | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
American Heart Association, Inc.
American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Commercial Services |
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
